Pharmacokinetic Drug Interaction Study of Sorafenib and Morphine in Rats.

drug–drug interaction morphine pharmacokinetics sorafenib sorafenib N-oxide

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
16 Dec 2021
Historique:
received: 19 11 2021
revised: 09 12 2021
accepted: 15 12 2021
entrez: 28 12 2021
pubmed: 29 12 2021
medline: 29 12 2021
Statut: epublish

Résumé

A combination of the tyrosine kinase inhibitor-sorafenib-and the opioid analgesic-morphine-can be found in the treatment of cancer patients. Since both are substrates of P-glycoprotein (P-gp), and sorafenib is also an inhibitor of P-gp, their co-administration may affect their pharmacokinetics, and thus the safety and efficacy of cancer therapy. Therefore, the aim of this study was to evaluate the potential pharmacokinetic drug-drug interactions between sorafenib and morphine using an animal model. The rats were divided into three groups that Received: sorafenib and morphine (I

Identifiants

pubmed: 34959453
pii: pharmaceutics13122172
doi: 10.3390/pharmaceutics13122172
pmc: PMC8707786
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Curr Pharm Des. 2011;17(26):2829-42
pubmed: 21827411
J Pharm Pharmacol. 2012 Apr;64(4):496-504
pubmed: 22420656
Pharm Res. 2015 Aug;32(8):2477-502
pubmed: 25972096
Biochem Pharmacol. 2017 Apr 1;129:85-95
pubmed: 28065859
Pharmacogenomics. 2014 Jul;15(10):1297-309
pubmed: 25155932
Cancer Res. 2015 Jul 1;75(13):2729-36
pubmed: 25952649
Pharmacol Rep. 2012;64(4):870-7
pubmed: 23087138
Pharm Res. 2001 Jul;18(7):957-63
pubmed: 11496955
Drug Metab Dispos. 2019 Feb;47(2):135-144
pubmed: 30442649
Liver Int. 2020 Jan;40(1):32-44
pubmed: 31654604
Clin Pharmacol Ther. 2006 Apr;79(4):316-24
pubmed: 16580900
Br J Clin Pharmacol. 2000 Sep;50(3):237-46
pubmed: 10971308
Anesthesiology. 2002 Apr;96(4):913-20
pubmed: 11964599
Anesthesiology. 2013 Oct;119(4):941-53
pubmed: 23851346
J Pain Palliat Care Pharmacother. 2012 Dec;26(4):362-7
pubmed: 23216174
J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Sep 25;809(1):99-103
pubmed: 15282098
Biochem Pharmacol. 2013 Sep 1;86(5):666-78
pubmed: 23835420
Eur J Clin Pharmacol. 2020 Apr;76(4):579-587
pubmed: 31932871
Anesthesiology. 2000 May;92(5):1392-9
pubmed: 10781286
Nat Rev Dis Primers. 2017 Mar 09;3:17009
pubmed: 28276433
Pharmacogenet Genomics. 2017 Jun;27(6):240-246
pubmed: 28362716
J Neurochem. 2003 Sep;86(6):1564-7
pubmed: 12950465
J Pain Palliat Care Pharmacother. 2013 Aug;27(3):261-7
pubmed: 23879227
Br J Pharmacol. 1999 Oct;128(3):563-8
pubmed: 10516633
Expert Rev Gastroenterol Hepatol. 2019 Feb;13(2):179-187
pubmed: 30791782
Biochem Pharmacol. 1999 Sep 15;58(6):951-7
pubmed: 10509747
Pharmacol Rep. 2020 Feb;72(1):254-259
pubmed: 32016844
Clin Pharmacol Ther. 2020 Jan;107(1):227-237
pubmed: 31350763
Psychopharmacology (Berl). 2014 Aug;231(16):3139-49
pubmed: 24705903
Eur J Pharmacol. 2002 Apr 5;440(1):7-16
pubmed: 11959083
Drug Metab Pharmacokinet. 2020 Feb;35(1):2-11
pubmed: 31996310
Pharm Res. 1998 Apr;15(4):599-605
pubmed: 9587957
Oncol Ther. 2020 Dec;8(2):251-259
pubmed: 32894414
Mol Pharmacol. 2007 Aug;72(2):387-94
pubmed: 17485564
Lancet Oncol. 2014 Jul;15(8):e315-26
pubmed: 24988935
Metabolites. 2021 Jan 27;11(2):
pubmed: 33513941
Life Sci. 2000;66(4):PL47-51
pubmed: 10665989
Xenobiotica. 2016 Jul;46(7):651-658
pubmed: 26582036
J Pharm Pharmacol. 2010 Mar;62(3):310-4
pubmed: 20487213
Biomed Pharmacother. 2020 Oct;130:110530
pubmed: 32712531
In Vivo. 2017 Sep-Oct;31(5):811-817
pubmed: 28882946
Lancet. 2016 Dec 3;388(10061):2783-2795
pubmed: 27240885
J Pharmacol Sci. 2007 Dec;105(4):353-60
pubmed: 18071274
Pharm Res. 2000 Jun;17(6):749-53
pubmed: 10955852
J Vet Pharmacol Ther. 2011 Oct;34(5):417-23
pubmed: 21241325
Metab Brain Dis. 2012 Mar;27(1):1-5
pubmed: 22193538
J Clin Invest. 1995 Oct;96(4):1698-705
pubmed: 7560060
Pharm Biol. 2017 Dec;55(1):1863-1867
pubmed: 28614959
Br J Clin Pharmacol. 2015 Feb;79(2):241-53
pubmed: 25125025
J Neurochem. 2002 Oct;83(2):241-8
pubmed: 12423235
Invest New Drugs. 2009 Feb;27(1):31-40
pubmed: 18449471
Clin Pharmacol Ther. 2008 Apr;83(4):559-66
pubmed: 17898703

Auteurs

Agnieszka Karbownik (A)

Department of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, 14 Św. Marii Magdaleny Str., 61-861 Poznań, Poland.

Danuta Szkutnik-Fiedler (D)

Department of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, 14 Św. Marii Magdaleny Str., 61-861 Poznań, Poland.

Tomasz Grabowski (T)

Preclinical Development, Polpharma Biologics SA, Trzy Lipy 3, 80-172 Gdańsk, Poland.

Anna Wolc (A)

Department of Animal Science, Iowa State University, 239E Kildee Hall, Ames, IA 50011, USA.
Research and Development, Hy-Line International, 2583 240th Street, Dallas Center, IA 50063, USA.

Joanna Stanisławiak-Rudowicz (J)

Department of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, 14 Św. Marii Magdaleny Str., 61-861 Poznań, Poland.
Department of Gynecological Oncology, University Hospital of Lord's Transfiguration, Poznań University of Medical Sciences, 84/86 Szamarzewskiego Str., 60-101 Poznań, Poland.

Radosław Jaźwiec (R)

Laboratory of Mass Spectrometry, Institute of Biochemistry and Biophysics PAS, Polish Academy of Sciences, 5A Pawińskiego Str., 02-106 Warsaw, Poland.

Edmund Grześkowiak (E)

Department of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, 14 Św. Marii Magdaleny Str., 61-861 Poznań, Poland.

Edyta Szałek (E)

Department of Clinical Pharmacy and Biopharmacy, Poznań University of Medical Sciences, 14 Św. Marii Magdaleny Str., 61-861 Poznań, Poland.

Classifications MeSH